EDGAR·FLOW

Endovia Health Sciences, Inc. — Form 8-K

Filed October 5, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
The FDA Center for Veterinary Medicine determined that Endovia and Lupvindol's CannEpil (CBD/THC oral solution) qualifies as a Minor Use under the MUMS program for canine bone cancer pain, establishing eligibility for conditional approval. A formal pre-submission FDA conference is scheduled for November 19, 2026, and the companies are establishing U.S. manufacturing capabilities targeting a potential 2027 veterinary launch, subject to regulatory approval.
Why this rating

Major regulatory milestone for $6.5M company: MUMS qualification meaningfully derisks path to market, enables earlier conditional approval vs full approval, and establishes clear 2027 timeline. Significant relative to company size; still pre-approval and execution-dependent.

Tradability signal
NO TRADE

No trade: price $0.16 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$0.17 ▲ 5.49%
at our read · unknown
$0.17
+10 min · unknown
$0.16 ▼ 3.56%
+30 min · unknown
$0.16 ▼ 3.50%
+1 hr · unknown
$0.16 ▼ 6.09%
+4 hrs · unknown
$0.16 ▼ 3.92%

The stock had already moved -5.20% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ EDVA · stock on Yahoo Finance ↗

See more from October 5, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.